Indian generics manufacturer Lupin Pharmaceuticals has signed an agreement with Australian biotech firm NeuClone to access cell line technology to be used to develop biosimilar drugs targeting cancer.
Lupin and Neuclone biosimilars agreement
Biosimilars/News
|
Posted 10/06/2011
0
Post your comment

The agreement involves transfer of technology, with NeuClone offering an exclusive proprietary mammalian Chinese hamster ovary cell line that will show a specific recombinant protein of interest in oncology to Lupin. This will also mean that scientific research staff from the Lupin Biological Research Programme will work with NeuClone at their facility.
Lupin is aggressively pursuing biosimilars and already has a separate research facility, with about 100 scientists, focused on biotechnology. The company expects in the next five years that 5-7% of its business will come from biosimilars and expects to have its first biosimilar on the market in 2012.
Recent estimates by IMS Health expect the global biosimilars market to exceed US$2 billion annually by 2015 [1], therefore, it is no wonder that most generic manufacturers and many originator companies are taking an interest in this lucrative area of the pharmaceutical market.
Reference
1. GaBI Online - Generics and Biosimilars Initiative. Generics and biosimilars to drive down drug spending [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 June 10]. Available from: www.gabionline.net/Pharma-News/Generics-and-biosimilars-to-drive-down-drug-spending
Source: The Hindu
Research
Biosimilars in low- and middle-income countries
Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)
General
The ustekinumab shift: biosimilars displace Stelara’s market leadership
Brazilian law establishes December 16 as National Biosimilar Day
EC approves eight biosimilars, eight more await final authorization

Biosimilars/News Posted 18/02/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment